{"DataElement":{"publicId":"6450479","version":"1","preferredName":"Leukemia Molecular Response Molecular Major Response BCR-ABL1 Fusion Protein Expression","preferredDefinition":"Text term to describe the disease status based on Major Molecular Response evaluation of BCR-ABL1 level by RQ-PCR with CML.","longName":"MMR_BCR-ABL1","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"3853618","version":"1","preferredName":"Leukemia Molecular Response","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853615v1.0:3853616v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853615","version":"1","preferredName":"Leukemia Response","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C3161:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CBFDC0-2AD3-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853616","version":"1","preferredName":"Molecular Analysis Evaluation","preferredDefinition":"Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C19770:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CBFDC0-2AE4-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3CBFDC0-2AF5-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6450474","version":"1","preferredName":"Molecular Major Response BCR-ABL1 Fusion Protein Expression","preferredDefinition":"A decrease in signs of cancer, supported by molecular analysis._Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","longName":"6450474v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"5000","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"MR5 is <0.0001% BCR-ABL1 level undetectable by RQ-PCR","valueDescription":"MR5 is <0.0001% BCR-ABL1 level undetectable by RQ-PCR","ValueMeaning":{"publicId":"6450475","version":"1","preferredName":"MR5 is <0.0001% BCR-ABL1 level undetectable by RQ-PCR","longName":"6450475","preferredDefinition":"MR5 is <0.0001% BCR-ABL1 level undetectable by RQ-PCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-16AF-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76DD3B65-16C8-59D7-E053-F662850A7688","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","deletedIndicator":"No"},{"value":"MR4.5 is <0.0032% BCR-ABL1 level by RQ-PCR","valueDescription":"MR4.5 is <0.0032% BCR-ABL1 level by RQ-PCR","ValueMeaning":{"publicId":"6450476","version":"1","preferredName":"MR4.5 is <0.0032% BCR-ABL1 level by RQ-PCR","longName":"6450476","preferredDefinition":"MR4.5 is <0.0032% BCR-ABL1 level by RQ-PCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-16D2-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76DD3B65-16EB-59D7-E053-F662850A7688","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","deletedIndicator":"No"},{"value":"MR4 is <0.01% BCR-ABL1 level by RQ-PCR","valueDescription":"MR4 is <0.01% BCR-ABL1 level by RQ-PCR","ValueMeaning":{"publicId":"6450477","version":"1","preferredName":"MR4 is <0.01% BCR-ABL1 level by RQ-PCR","longName":"6450477","preferredDefinition":"MR4 is <0.01% BCR-ABL1 level by RQ-PCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-16F5-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76DD3B65-170E-59D7-E053-F662850A7688","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","deletedIndicator":"No"},{"value":"M3 is <0.1% BCR-ABL1 level by RQ-PCR","valueDescription":"M3 is <0.1% BCR-ABL1 level by RQ-PCR","ValueMeaning":{"publicId":"6450478","version":"1","preferredName":"M3 is <0.1% BCR-ABL1 level by RQ-PCR","longName":"6450478","preferredDefinition":"M3 is <0.1% BCR-ABL1 level by RQ-PCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-1718-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76DD3B65-1731-59D7-E053-F662850A7688","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6450473","version":"1","preferredName":"Molecular Major Response BCR-ABL1 Fusion Protein Expression","preferredDefinition":"A decrease in signs of cancer, supported by molecular analysis.:Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","longName":"C123594:C36715","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Major Response","conceptCode":"C123594","definition":"A decrease in signs of cancer, supported by molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"BCR-ABL1 Fusion Protein Expression","conceptCode":"C36715","definition":"Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-1688-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"ONEDATA","dateModified":"2018-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76DD3B65-1699-59D7-E053-F662850A7688","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"LEEW","dateModified":"2018-09-28","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Major Molecular Response stat","type":"Preferred Question Text","description":"Major Molecular Response status during this observation period:","url":null,"context":"COG"},{"name":"COG CRF TEXT1","type":"Alternate Question Text","description":"Major Molecular Response status at baseline:","url":null,"context":"COG"},{"name":"COG CRF TEXT 2","type":"Alternate Question Text","description":"Molecular Response status at baseline:","url":null,"context":"COG"},{"name":"COG CRF TEXT 3","type":"Alternate Question Text","description":"Molecular Response status during this observation period:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76E0DE04-F4C3-79D9-E053-F662850A766F","latestVersionIndicator":"Yes","beginDate":"2018-09-27","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-27","modifiedBy":"LEEW","dateModified":"2018-11-20","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}